Home > List All Publishers > BioSeeker Group AB

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.
BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker Group clients and projects are kept confidential.

List of reports from BioSeeker Group AB

Cancer Immunotherapy beyond Monoclonals 9/1/2001 \| published by: BioSeeker Group AB ... valued at more than $15 billion in 1998, is projected to nearly double by 2003. Based on advances in cell and molecular biology, the number of therapeutic cancer targets in pipeline is rapidly increasing. Numerous ... \| more... Buy by the section \| Search inside this report	$2,261.25
Emerging Cancer Therapeutics 1/1/2002 \| published by: BioSeeker Group AB ... valued at more than $15 billion in 1998, is projected to nearly double by 2003. Based on advances in cell and molecular biology, the number of therapeutic cancer targets in pipeline is rapidly increasing. Numerous ... \| more... Search inside this report	$4,029.75
Commercializing on Tumor Antigens: Analytical Perspectives 2/1/2002 \| published by: BioSeeker Group AB ... tool for strategic planning in tumor antigen commercialization whether being a CEO, business developer at a biotech enterprise or an investment analyst at a VC firm. We have identified more than 60 tumor antigens that ... \| more... Buy by the section \| Search inside this report	$5,062.50
Pan-European Investors in Biotechnology 2/1/2002 \| published by: BioSeeker Group AB ... contact information: phone, fax, email, website and ordinary mail. More than 320 companies have their own website for in depth information about their activity. The companies in the report are indexed alphabetically, by country and ... \| more... Search inside this report	$538.65
The Competitive Landscape of Cancer Gene Therapy (2nd issue) 5/13/2002 \| published by: BioSeeker Group AB ... valued at more than $15 billion in 1998, is projected to nearly double by 2003. Based on advances in cell and molecular biology, the number of therapeutic cancer targets in pipeline is rapidly increasing. Numerous ... \| more... Buy by the section \| Search inside this report	$3,071.25
Ion Channel Assays in the Drug Discovery Process 6/3/2002 \| published by: BioSeeker Group AB ... available and future possibilities in ion channel assays, provides you with an outlook at the competitive landscape of companies in this field, and guides the user to technologies that suiting different segments of the drug ... \| more... Search inside this report	$3,408.75
Swedish Biopharma Industry - The Next Wave 9/17/2002 \| published by: BioSeeker Group AB ... Swedish Biopharma Industry-The Next Wave, BioSeeker Group analyzes in detail the pharmaceutical biotechnology (biopharma) industry segment in Sweden. In terms of numbers, biopharma is the second largest biotech industry segment in Sweden after the medical ... \| more... Search inside this report	$1,147.50
Swedish Biopharma Profiles 2002 9/25/2002 \| published by: BioSeeker Group AB ... development (R&D) or search and development (S&D) in Sweden. We also present which major disease groups are targeted and the geographical distribution of biopharma companies in Sweden. Each profile contains contact details, financial information covering ... \| more...	$471.15
R&D in Swedish Biopharma Companies 2002 9/25/2002 \| published by: BioSeeker Group AB ... in 52 identified biopharma companies in Sweden. The predominant disease groups for R&D in Swedish biopharma are: Inflammation / autoimmune, metabolic, cancer, infectious, and neurological diseases, whilst treatments for dermatitis, psoriasis, asthma and osteoporosis are ... \| more...	$492.75
The Next Generation of Antifungals: Triazoles vs. Peptides 10/8/2002 \| published by: BioSeeker Group AB ... available", they continue, and it is a requirement for fungicidal, broad spectrum, non-toxic, orally deliverable drugs to have a low cost. During the 1990's, the U.S. systemic antifungal market has grown 25% per year. The ... \| more... Search inside this report	$668.25
Fierce Competition for a Shrinking HCV Market 10/21/2002 \| published by: BioSeeker Group AB ... U.S. alone. Of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected ... \| more... Buy by the section \| Search inside this report	$911.25
Ion Channel Assays as Therapeutic Targets for Multiple Diseases 11/7/2002 \| published by: BioSeeker Group AB ... revealing the tissue specific distributions of ion channels, they will play a much more important role as therapeutic drug targets in the future. These advancements combined with cell-based assays providing biologically relevant information to genomic ... \| more... Search inside this report	$857.25
Ion Channels as Therapeutic Targets for Multiple Diseases 11/7/2002 \| published by: BioSeeker Group AB ... in transcription profiling revealing the tissue specific distributions of ion channels, they will play a much more important role as therapeutic drug targets in the future. These advancements combined with cell-based assays providing biologically relevant ... \| more...	$924.75
Future HCV Drug Discovery Technologies 11/25/2002 \| published by: BioSeeker Group AB ... both by academic groups and private companies, which has resulted in a drastic improvement of the possibilities for in vivo research. The main obstacle has clearly been difficulty of achieving viral replication in the laboratory ... \| more...	$735.75
New Targets and Drug Discovery Platforms in Antifungal R&D 11/25/2002 \| published by: BioSeeker Group AB ... of fungal drug resistant, drug-related toxicity, hazardous drug-drug interactions and non-optimal pharmacokinetics. This makes them inadequate in prophylactic treatments for immuno-compromised patient, such as HIV infected and patients with ongoing cancer or transplantation treatment. The ... \| more...	$1,005.75
Market and Sales Guide to the Swedish Biotech Market 2003 2/5/2003 \| published by: BioSeeker Group AB ... may be of potential value for your business purposes. We provide you with information important for deciding on the “buying power” of each of the 13 industry segments and the 330 companies included in this ... \| more... Buy by the section \| Search inside this report	$2,018.25
Molecular Approaches Towards HCV Therapy - The Complete Guide 4/12/2003 \| published by: BioSeeker Group AB ... The understanding of hepatitis C at a molecular level has also opened the door for more targeted development of a prophylactic or therapeutic HCV vaccine. According to the CDC, nearly four million people are or ... \| more...	$2,700.00
Marketing and Sales Guide to the Danish Biotech Market 2003 5/16/2003 \| published by: BioSeeker Group AB ... information important for assessing the "buying power" of each of the 14 industry segments and 160 companies included in this report. Up to three years of financial data from public as well as private companies ... \| more...	$1,680.75
New Lines of Attack in Cancer Anti-Angiogenesis 6/4/2003 \| published by: BioSeeker Group AB ... and neovascularisation via techniques aimed at inhibiting new blood vessel growth or destroying already existing tumor vasculature. Despite early enthusiasm for angiogenesis inhibitors as safe and effective anticancer drugs, results of several completed Phase III ... \| more... Buy by the section \| Search inside this report	$2,632.50
A Shift in Cancer Immunotherapy Strategies? 7/25/2003 \| published by: BioSeeker Group AB ... projects (more 425 clinical trials of which 60 are in phase III) in order to elucidate changes in strategies for cancer immunotherapy. Conference information from the latest meeting held by the American Society of Clinical ... \| more... Buy by the section \| Search inside this report	$3,712.50
National Swedish Biotech Address Registry 9/8/2003 \| published by: BioSeeker Group AB ... 440 biotech companies. With no less than 17 different search parameters, NSBAR is built in a way that easily helps you to locate your target group with very high precision. Contact data on each position ... \| more...	$3,307.50
The Prostate Cancer R&D Database 9/18/2003 \| published by: BioSeeker Group AB ... essential to make it as complete as possible in order to analyze and draw correct conclusions from the field. For your convenience, BioSeeker Group has identified and structured more than 300 industry related prostate cancer ... \| more...	$3,982.50
Tumor Antigen & Cancer Vaccine Database 10/7/2003 \| published by: BioSeeker Group AB ... therapies, anti-idiotypic antibodies and gene therapies. BioSeeker is also providing in-depth knowledge of industry efforts in tumor antigen discovery, delivery, and presentation; as well as different techniques for improving the immune response. Decision-making requires a ... \| more...	$3,982.50
The Future Battle Between Biopharmaceuticals and Biogenerics 10/30/2003 \| published by: BioSeeker Group AB ... have reviewed the positions of the FDA and the EMEA, the views on regulatory precedent cases from the biologics industry, the possible route of a comparability study approval, the scope of clinical trial necessary, and ... \| more...	$3,375.00
The Melanoma R&D Database 11/10/2003 \| published by: BioSeeker Group AB ... to make it as complete as possible in order to analyze and draw correct conclusions from the field. For your convenience, BioSeeker Group has identified and structured more than 230 industry related melanoma R&D projects, ... \| more...	$3,982.50

< prev 1 2 3 4 5 6 7 8 9 10 next >